Results 201 to 210 of about 203,196 (295)

Anti‐inflammatory effects of physical stimuli: The central role of networks in shaping the future of pharmacological research

open access: yesBritish Journal of Pharmacology, EarlyView.
Addressing complexity in the study of life sciences through Systems Biology and Systems Medicine has been transformative, making Systems Pharmacology the next logical step. In this review, we focus on physical stimuli, whose potential in pharmacology has been neglected, despite demonstrated therapeutic properties.
Veronica Paparozzi   +10 more
wiley   +1 more source

Immune‐related toxicity profile after haematopoietic stem cell transplantation in patients with B‐ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab

open access: yes
British Journal of Haematology, EarlyView.
Olayinka Okeleji   +7 more
wiley   +1 more source

Induction of IL‐9‐producing CD8+ T cells by ascochlorin derivatives

open access: yesBritish Journal of Pharmacology, EarlyView.
A newly synthesised ascochlorin derivative, N184, induces small amounts of IL‐9‐producing CD8+ T cells. N184 improved the survival of CD8+ T cells and enhanced their antitumour activity, partially in an IL‐9‐dependent manner. The antitumour effect was completely dependent on IFNγ secretion rather than the cytotoxic activity of CD8+ T cells.
Natsumi Imano   +5 more
wiley   +1 more source

Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Bruton tyrosine kinase (Btk) is essential for B cell function. Its role in myeloid cells is less understood. Greater insights into Btk significance in myeloid cells are needed to evaluate its potential as a therapeutic target during the effector phase of antibody‐induced autoimmune diseases, where inhibiting autoantibody ...
Henning Olbrich   +7 more
wiley   +1 more source

Bone Marrow Edema and Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia. [PDF]

open access: yesDiagnostics (Basel)
Russo S   +5 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

Polycythaemic panmyelosis in chronic myeloid leukaemia

open access: yes
British Journal of Haematology, EarlyView.
George Mason   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy